GSK’s ViiV Healthcare and its bimonthly pre-exposure prophylaxis (PrEP) medicine Apretude had to make room for another ...

In separate announcements Wednesday, a pair of agencies shared business updates both aimed at leveling up their respective ...

With sales of potential blockbuster Lokelma scaling up, AstraZeneca is bolstering its production of the hyperkalemia ...

Codis, born from the fusion of U.S.-based Particle Dynamics and a U.K. | In addition to substantial spray drying capacity, ...

Brexafemme (ibrexafungerp) partners GSK and Scynexis have worked out their quarrel related to a clinical trial that was previously put on hold, leaving Scynexis with a $22 million payout. | Through ...

Halozyme Therapeutics has been busy. While fighting a patent dispute with Merck & Co. | Halozyme scoured very broadly for ...

Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about ...

It appears problems at Novo Nordisk’s recently acquired manufacturing facility in Indiana aren’t going to be solved any time ...

In a statement, Cabaletta CEO Steven Nichtberger, M.D., highlighted Gavel’s previous experience commercializing cell ...

Sometimes, an agency’s staffing needs can lead to the discovery of a new passion. | In a Q&A for Fierce Pharma Marketing’s ...

With the launch of a new branded initiative, Bristol Myers Squibb is crafting a recipe for both ramping up its Cobenfy ...

State privacy laws are reshaping the way pharmaceutical companies reach patients, said Katie Carr, chief revenue officer at ...